Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paroxetine Concentration-QT Study in Healthy Adults
NCT06065735Phase 1Completed
- Sponsor
- GSK
- Start
- Oct 2023
- Primary completion
- Jan 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paroxetine in anxiety disorders, sponsored by GSK. Primary endpoint: Change From Baseline in Corrected QT Interval by Fridericia. Started Oct 2023; status: completed.
02
Drugs
paroxetine
03
Conditions
anxiety disorders
Beyond the preview
Go deeper on NCT06065735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06065735.